According to the study, the primary efficacy endpoint—successful device delivery and inflation at the perforation site, control of extravasation, and preservation of antegrade coronary flow ...

WAYNE, Pa. - Teleflex Incorporated (NYSE: TFX), a global provider of medical technologies with annual revenues of $3.05 billion, has announced preliminary results from its Ringer™ PBC study, which ...

David E. Kandzari of Piedmont Heart Institute, highlighted the potential of the Ringer™ PBC device in managing coronary perforations during percutaneous coronary intervention (PCI) procedures.

Kandzari. “Treatment options for patients with coronary artery perforations during PCI cases have been limited to date, and this trial points the way to developing dedicated devices.” ...